1. HBW Insight
  2. >>Health
  3. >>Business

Perrigo Returns To 'Model' For Success, Expects Surprises From 2020 Launches

 
• By Malcolm Spicer

Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."

Rolled House Blueprints and Construction Plans. - Image

After a "fun first year" at Perrigo Co. PLC's helm, Murray Kessler says the OTC private label giant that has struggled to grow earnings for several years will have surprises in early 2020 with product launches.

"I think the world will be surprised, when I come out in the beginning of the year, to see how...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

People On The Move: Appointments At Klosterfrau, Haleon, Opella

 
• By Tom Gallen

A round-up of the latest consumer health industry appointments: Kloserfrau makes changes to management in Germany; Haleon hires Pakistan head; Opella names Americas leader.

Stada Held Back By Weak Cough & Cold Season

 
• By Tom Gallen

While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.

US Consumer Health, Beauty Sectors: Expecting Tariff Policy Changes, Buckling Up For The Ride

 
• By Malcolm Spicer

As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.

Galenica’s Verfora Gets Off To Flying Start In Swiss CHC Market

 
• By Tom Gallen

Verfora grows almost 10-times faster than the Swiss consumer health market in the opening months of 2025.

More from Health

Senators’ Questions Stray Far From OMUFA During HELP Committee Hearing On Reauthorization

 
• By Malcolm Spicer

HELP members state frustration with layoffs at FDA and pose questions about topics from generic drug approvals to OTC switches, and from manufacturing location labeling to whether the federal agencies intrude on US consumers. Still, acting CDER director Jacqueline Corrigan-Curay makes clear the resu

People On The Move: Appointments At Klosterfrau, Haleon, Opella

 
• By Tom Gallen

A round-up of the latest consumer health industry appointments: Kloserfrau makes changes to management in Germany; Haleon hires Pakistan head; Opella names Americas leader.

AESGP Annual Meeting: Commission Must ‘Think Carefully’ Before Reverse-Switching Antimicrobials

 
• By David Ridley

If the European Commission is serious about improving the competitiveness of the European Union, it should ditch the idea of making commonly used OTC antimicrobials like thrush treatments and cold sore creams prescription-only, warns Greek Medicines Agency president Evangelos Manolopoulos